Stock IGMS IGM BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company IGM Biosciences, Inc.

Equities

IGMS

US4495851085

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
7.2 USD -2.83% Intraday chart for IGM Biosciences, Inc. -21.40% -13.36%
Apr. 17 IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets MT
Apr. 17 IGM Biosciences, Inc. Announces Refocusing of Sanofi Collaboration CI

Business Summary

IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.

Number of employees: 224

Sales per Business

USD in Million2022Weight2023Weight Delta
Engineered Immunoglobulin M Antibodies
100.0 %
1 100.0 % 2 100.0 % +99.25%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
1 100.0 % 2 100.0 % +99.25%

Managers

Managers TitleAgeSince
Fred Schwarzer CEO
 Chief Executive Officer 72 03-01-31
Misbah Tahir DFI
 Director of Finance/CFO 49 18-12-31
T. S. Harigopal COO
 Chief Operating Officer - 20-12-31
Chris Takimoto CTO
 Chief Tech/Sci/R&D Officer 65 21-07-28
Bruce Keyt CTO
 Chief Tech/Sci/R&D Officer 71 09-12-31
Lisa Wax LAW
 General Counsel - 20-12-31
Angus M. Sinclair PRN
 Corporate Officer/Principal - 17-12-31
George Gauthier PRN
 Corporate Officer/Principal 52 21-04-11
Steven Weber AUD
 Comptroller/Controller/Auditor 48 22-02-28
Paul Graffagnino LAW
 General Counsel - 20-12-31

Members of the board

Members of the board TitleAgeSince
Felix Baker BRD
 Director/Board Member 55 21-01-25
M. Wilsey BRD
 Director/Board Member 71 19-01-30
Fred Schwarzer CEO
 Chief Executive Officer 72 03-01-31
Michael Lee BRD
 Director/Board Member 45 19-06-30
Julie Hambleton BRD
 Director/Board Member 66 18-08-14
Jakob Haldor Topsøe BRD
 Director/Board Member 55 18-07-31
Christina Teng Topsøe BRD
 Director/Board Member 43 18-07-31
William Strohl BRD
 Director/Board Member 71 18-07-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 25,500,383 0 0 36.68 %
Stock B 1 33,286,205 21,560,380 ( 64.77 %) 0

Shareholders

NameEquities%Valuation
Topsøe Holding A/S
31.28 %
10,410,364 31.28 % 100 M $
Baker Bros. Advisors LP
12.28 %
4,088,100 12.28 % 39 M $
Baker Bros. Advisors LP
11.09 %
3,691,011 11.09 % 36 M $
T. Rowe Price Associates, Inc. (Investment Management)
10.23 %
3,403,714 10.23 % 33 M $
T. Rowe Price International Ltd.
9.794 %
3,260,022 9.794 % 31 M $
Artal Group SA
9.314 %
3,100,422 9.314 % 30 M $
Redmile Group LLC
9.248 %
3,078,332 9.248 % 30 M $
Redmile Group LLC
8.927 %
2,971,542 8.927 % 29 M $
Fidelity Management & Research Co. LLC
5.103 %
1,698,506 5.103 % 16 M $
Goldman Sachs Asset Management LP
3.126 %
1,040,509 3.126 % 10 M $
NameEquities%Valuation
Baker Bros. Advisors LP
35.11 %
10,720,924 35.11 % 103 M $
Redmile Group LLC
23.58 %
7,199,325 23.58 % 69 M $
Topsøe Holding A/S
16.52 %
5,044,295 16.52 % 49 M $

Company contact information

IGM Biosciences, Inc.

325 East Middlefield Road

94043, Mountain View

+650 965 7873

http://www.igmbio.com
address IGM Biosciences, Inc.(IGMS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for IGM Biosciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
7.41 USD
Average target price
21.6 USD
Spread / Average Target
+191.50%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
IGM BIOSCIENCES, INC. Stock IGM Biosciences, Inc.
-13.36% 437M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.10% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.11% 96.07B
ARGENX SE Stock argenx SE
-1.80% 21.66B
BIONTECH SE Stock BioNTech SE
-17.75% 20.77B
GENMAB A/S Stock Genmab A/S
-6.91% 18.53B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.00% 16.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-28.19% 13.79B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.18% 13.33B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+19.90% 10.94B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. IGMS Stock
  4. Company IGM Biosciences, Inc.